Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 2565 · · 11 pages · English
Summary by 6ix AI
It includes information on the company's authorized and registered share capital, confirming no changes during the month. The report also confirms compliance with public float requirements for the listed shares.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from PegBio
- 2026 Interim Report
- Change in use of proceeds from the global offering
- Proposed change of auditor
- Voluntary announcement core product Visepegenatide injection passed the preliminary review in accordance with the 2026 national reimbursement drug list adjustment
- Next Day Disclosure Return
Later from PegBio
- (1) Proposed removal of auditor (2) proposed appointment of auditor (3) proposed change in use of proceeds from the global offering and (4) notice of the 2026 first extraordinary general meeting
- Notice of the 2026 first extraordinary general meeting
- Form of proxy for use at the 2026 first extraordinary general meeting to be held on Thursday, November 12, 2026
Follow PegBio into a list and get an email when it puts out news.
Follow PegBio